Paladin Labs Files Long-Form Prospectus

On May 3, 2002, Paladin Labs Inc., a pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market, filed a final long-form prospectus to qualify the distribution of common shares issuable upon the exercise of its previously issued special warrants. Paladin had closed the private placement portion of this $21 million special warrant offering on March 21, 2002.

The financing was co-led by CIBC World Markets Inc. and Yorkton Securities Inc., and included Desjardins Securities Inc., BMO Nesbitt Burns Inc., National Bank Financial Inc. and Sprott Securities Inc. Paladin issued 2,205,500 special warrants, including an over-allotment option of 100,000 special warrants, at $9.50 for total gross proceeds of $20,952,250. Each special warrant was exercisable, for no additional consideration, into one common share of Paladin. One-half of the proceeds of the financing were held in escrow until the final prospectus had been cleared by the applicable securities commissions.

Paladin was represented by Fraser Milner Casgrain LLP in Montreal, with a team consisting of Charles R. Spector, Joanie Schwartz and √Člise Renaud. The agents were represented by Ogilvy Renault also in Montreal, with a team led by Norman Steinberg, Angelo Noce and Luc Boucher.